Objective: The objective of this study was to determine the prevalence of frailty in patients with peripheral arterial disease (PAD) and to compare the incremental value of six non-performance-based frailty scales to predict poor outcomes after interventions for PAD.
Methods: FRailty Assessment In Lower Extremity arterial Disease (FRAILED) was a prospective cohort study designed to examine frailty in patients with PAD. Consecutive patients undergoing endovascular or open interventions for PAD (Rutherford class $3) were enrolled. Frailty was assessed using the Edmonton Frailty Scale, FRAIL scale, Groningen Frailty Indicator (GFI), modified Frailty Index, Multidimensional Prognostic Index, and modified Essential Frailty Toolset (mEFT). The primary outcome was a composite of all-cause mortality and morbidity.
Results: The cohort consisted of 149 older adults with a mean age of 70.5 6 10.8 years. Patients with claudication and critical ischemia accounted for 40% (n ¼ 60) and 60% (n ¼ 89), respectively. Depending on the scale, the prevalence of frailty ranged from 37% to 70%. The incidence of all-cause mortality was 6.3% in the cohort during a median follow-up of 1.3 years. After adjusting for age, sex, predicted operative risk, diagnosis, and procedure type, the frailty scales with the greatest incremental value for mortality and morbidity were found to be the GFI (standardized adjusted odds ratio, 3.22; 95% confidence interval, 1.32-8.86; Bayesian information criterion, 88.7) and the mEFT (standardized adjusted odds ratio, 1.99; 95% confidence interval, 1.01-3.97; Bayesian information criterion, 93.2). The four other frailty scales were not statistically significant in the multivariable logistic models.
Conclusions: The prevalence of frailty and the prognostic impact of frailty varied by the scale used. The GFI and mEFT performed well and were most predictive of mortality and morbidity in patients with PAD undergoing interventions. The GFI and mEFT may be more appropriate to use in clinical practice when assessing frailty in patients with PAD.
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